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Abstract
Background: Loss of normal cell cycle control is an early event in the evolution of cancer. The expression of
cyclin-dependent kinase (CDK) inhibitors p16 and p27 has been previously associated with progression of prostate
cancer (PC). 70 patients diagnosed with early stage PCwere treated with radical prostatectomy (RP) at our
institution and their tumor specimens were immunohistochemically evaluated for expression of p16 and p27.
Available clinical data of time to PSA recurrence were correlated with the examined parameters and combined
with pre-operative PSA level, Gleason score and pathological TNM (pT) stage assessment.
Results: Nuclear overexpression of p16 was not associated with time to biochemical failure (BF) (p = 0.572). Same
was the case for nuclear p27 overexpression (p = 1.000). Also, no significant correlations were found between
either p16 or p27, and pre-operative PSA level, pT stage and Gleason grade. pT stage emerged as the only
independent prognostic factor for biochemical recurrence (p = 0.01).
Conclusions: These data question previously reported data supporting the prognostic relevance of both p16 and
p27 proteins in early PC.
Background
There is increasing evidence that cell cycle regulators are
disrupted in human cancers [1]. The cell cycle is governed
by cyclin-dependent kinases (CDKs), the activities of
which are regulated by binding of positive effectors, the
cyclins [2]; by negative regulators, the CDK inhibitors [3]
and by phosphorylation and dephosphorylation events.
p16 protein, encoded by the INK4A gene mapping to
the 9p21 region [4,5] acts as a negative cell cycle regulator.
Specific mechanisms may contribute to p16 altered
expression, overcoming p16-mediated tumor suppressor
activities. Unlike other primary tumors, INK4A inactiva-
tion, through deletions, mutations, or promoter methyla-
tion, seems to be an infrequent event in primary prostate
cancer (PC) [6]. In contrast, the more frequent alterations
of p16 in metastatic disease suggest that this might be a
late event during the progression of some prostate
carcinomas. It seems that p16 is overexpressed rather than
lost in a large proportion of prostate carcinomas as p16
protein expression was increased in a majority of adeno-
carcinomas of the prostate and in prostate intra-epithelial
neoplasia (PIN) when compared with surrounding benign
glands [7]. Loss of transcriptional repression in the pre-
sence of inactivating mutations in the retinoblastoma (RB)
gene is the most well-defined mechanism of p16INK4A
overexpression [8]. p16 expression in premalignant lesions
and carcinomas but not in normal or benign tissues
implies a role of p16INK4A detection in the diagnosis of
difficult cases of PIN and PC [9].
p27Kip1 is another CDK inhibitor that negatively regu-
lates cell proliferation by mediating cell cycle arrest in G1.
It has been suggested that decreased expression of the
p27Kip1 protein may contribute to the development of
human malignancies due to loss of critical anti-prolifera-
tive mechanisms. Unlike other CDK inhibitor genes, the
p27Kip1 gene is rarely mutated in human cancers [10].
Instead, loss of p27Kip1 appears to occur through acceler-
ated degradation by the ubiquitin-proteasome pathway.
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with advancing histological aggressiveness, implicating
deregulation of p27 in prostate tumor progression [11,12].
Down-regulation of expression of p27Kip1 in neoplastic
progression from pre-invasive lesions through invasive
carcinoma and metastases occurs in the early phases of
neoplastic PC evolution [13].
There seems to be a close molecular association between
these two CDK inhibitor proteins as p16INK4A-mediated
growth inhibition may occur only when cyclin E/Cdk2
complexes are inactivated concurrently by p27Kip1 [14].
Reversely, loss of p16 seems to contribute to p27 seques-
tration by cyclin D1-CDK 4 complexes and confers poor
prognosis in hepatocellular carcinoma [15]. Progressive
and sustained increases in both p27 and p16 protein
expression are considered to occur as mid-to-late events
during evolution of PC [16].
In this study we sought to determine whether there is a
clinically relevant interrelation based on immunohisto-
chemical detection of p16 and p27 in radical prostatect-
omy (RP) specimens of hormone-naïve PC patients.
Associations between p16 and p27 phenotypes and clin-
ico-pathological variables were also studied to further
define their potential use as prognostic indicators of bio-
chemical failure (BF) in early PC.
Methods
Patients
The study enrolled patients over 18 years old with histolo-
gically newly diagnosed, early stage PC, admitted to the
Department of Urology of our Institution. All patients of
the study underwent an open retropubic RP. Patients were
hormone- and treatment- naïve at the time of surgery. No
history of previous reproductive or endocrine diseases was
reported. Written informed consent was provided by all
patients before study entry. The study was approved by
the Ethics and Scientific Committees of our Institution.
Patient demographics (age) as well as clinico-pathological
parameters, including pre-operative PSA level, pathologi-
cal TNM (pT) stage and Gleason score of the primary
tumor, PSA recurrence and survival data were recorded.
The RP specimens were fixed in 10% buffered formalin
solution and embedded in paraffin blocks. The complete
sampling scheme with routine sections was used. H&E -
stained tissue sections from 70 patients were examined
by a single, blinded histopathologist and evaluation of
histopathological characteristics was made according to
recommendations of the 2004 World Health Organiza-
tion (WHO) - sponsored International Consultation on
Prediction of Patients Outcome in Prostate Cancer meet-
ing [17]. Cases were grouped into 2 Gleason groups, low
(≤ 7, 7 = 3+4; n =5 0 )a n dh i g h( ≥ 7, 7 = 4+3; n = 20) as
there were no lower Gleason score (2, 3, 4) samples
based on the established 3-group histopathological
criteria of current literature (low, medium and high).
Cases were also grouped according to pT stage into
either organ confined disease (pT ≤ 2; n =4 2 )o r
advanced tumors extending beyond the prostatic capsule
(pT > 2; n = 28). Patients were categorized into 3 sub-
groups according to pre-operative PSA level (< 5 ng/ml,
n = 14; 5-10 ng/ml, n =4 8a n d>1 0n g / m l ,n = 8). Inter-
mediate risk PC is generally considered with a PSA of 10-
20 ng/ml, but we explored whether there is any differ-
ence in PSA relapse-free survival between subgroups of <
5, 5-10 and > 10 ng/ml within our cohort of low-to-inter-
mediate risk for PSA recurrence, as indicated by
the range of pre-operative PSA values (2.8-23.9 ng/ml).
The majority of patients featured a negative lymph node
status (n = 53). The latter was not included in the statisti-
cal analyses due to missing information regarding a sig-
nificant number of patients (n = 11 or 15.7%). Patients’
clinical and pathological characteristics are depicted in
Table 1.
Immunohistochemistry
Sections (4 μm) from selected paraffin blocks of each
case were obtained. Sections were deparaffinised in
xylene and rehydrated through decreasing alcohols. Anti-
gen unmasking for p16 and p27 was achieved by boiling
sections in Trilogy reagent (Cell Marque, Rocklin, Calif)
for a total of 1 hour in a commercially available steamer.
After quenching endogenous peroxidase with 3% hydro-
gen peroxide solution for 10 min, slides were incubated
at room temperature for 30 minutes with the following
primary mouse monoclonal antibodies: against p16
[ c l o n eE 6 H 4 ,m o u s em o n o c l o n a l ,C I N T E C ,r e a d yt ou s e
(RTU)] and anti-p27 (clone 5X53G8, mouse monoclonal,
DAKO, Denmark, in 1:50 dilution). Staining was devel-
oped with substrate chromogen solution (EnVision,
DAKO, Glostrup, Denmark) and diaminobenzidine for
10 minutes. Slides were counterstained with Harris
hematoxylin for 1 minute, dehydrated, and mounted with
DPX solution. p16 immunostaining was nuclear. The
Table 1 Patients’ clinical and pathological characteristics
Variable Subgroup n (%)
age (years) ≤ 65 31 (44.3)
range 47-75 > 65 39 (55.7)
pre-op PSA (ng/ml) < 5 14 (20.0)
range 2.8-23.9 5-10 48 (68.6)
> 10 8 (11.4)
pT stage ≤ 2 42 (60.0)
> 2 28 (40.0)
Gleason score ≤ 7 (3+4) 50 (46.8)
≥ 7 (4+3) 20 (44.2)
pre-op PSA, pre-operative PSA; pT stage, pathologic TNM stage
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according to the percentage of immunostained neoplastic
cells: negative (0), less than 30% (1), 30% to 70% (2) and
more than 70% (3). p27 immunostaining was nuclear.
The extent of immunostaining was categorized into 2
groups according to the percentage of immunostained
neoplastic cells: less than 70% (1), and more than 70%
(2). Groups 1, 2 and 3 of p16 expression were merged
together for statistical analysis. Immunohistochemical
reaction was glandular for all tested parameters (p16,
p27). The normal adjacent prostate gland was used as
negative internal control marker for p16 expression and
positive control for p27 expression.
Study endpoints
Our objective was to investigate possible interrelations
between immunohistochemical expression of p16 and p27
as well as their potential correlations with pre-operative
PSA level, Gleason score and pT stage in patients with
hormone naïve PC undergoing RP. We further examined
the putative prognostic role of these parameters in associa-
tion with time to PSA relapse. The response variable, time
to BF, was defined as the time from RP to the time of the
first detectable (non-zero) PSA measurement. To confirm
PSA relapse, three consecutive increases of PSA were
required; however, the time of relapse was defined as the
time of the first detectable PSA measurement [18].
Statistical analyses
The Fisher’s, Pearson’s Chi-squared and c
2 tests were used
to explore associations between p16, p27 expression pat-
terns and pre-operative PSA level, Gleason score, and pT
stage. The Kaplan-Meier method was used to determine
the effect of each categorical variable on biochemical
relapse-free survival, and the log-rank test was used to
compare recurrence-free survival differences within each
variable. For PSA recurrence-free survival analysis at the
multivariate level the Cox proportional hazards model was
used to estimate hazard ratios (HR) with 95% confidence
intervals (CI). Statistical significance was determined by
using two-tailed p-values and was reported at p < 0.05
level. Statistical analysis was performed using SPSS (SPSS
for Windows, version 15.0, SPSS, Chicago, IL).
Results
Thirty-seven (53%) patients developed PSA recurrence
during follow up, thirty-three (47%) did not have a PSA
relapse and two patients (2.8%) expired. The estimated
median follow up time, as calculated by the reverse
Kaplan-Meier method was 30 months (range 12-86) while
the median time to BF was 56 months (range 1-74).
According to level of p16 expression, patients were
divided into a group of negative nuclear staining (n = 54,
77.1%) and another of positive nuclear p16 immunohisto-
chemical expression (n = 16, 22.9%). In univariate analysis,
we observed no significant association of p16 with Gleason
score (p = 0.565) or pT stage (p = 0.394) (Table 2). Further,
there were no statistically significant correlations between
p16 and pre-operative PSA levels (Table 2). The expression
of p16 was not associated with time to BF (p = 0.572).
p27 expression was distributed in two groups of either
low (n = 59, 84.3%) or high (n = 11, 15.7%) nuclear
immunoreactivity. p27 positivity did not correlate with
neither Gleason score (p = 1.000) nor pT stage (p =
0.328) in univariate analysis (Table 2). p27 was not pre-
dictive of PSA biochemical recurrence (p = 1.000) and
there were no statistically significant correlations
between p27 and pre-operative PSA levels (Table 2).
p16 and p27 expression did not present any statistically
significant interrelation (p = 0.705).
Immunohistochemical expression patterns of p16 and
p27 are depicted in Figures 1, 2 and 3, 4 respectively.
pT stage and Gleason score were directly interrelated
(p = 0.028) and were both inversely related with time to
BF (p < 0.001 and p = 0.008 respectively). pT stage was
directly associated with pre-operative PSA levels < 5 ng/
ml (p = 0.016), 5-10 ng/ml (p = 0.007) and > 10 ng/ml
(p = 0.054). There were no statistically significant corre-
lations between pre-operative PSA levels and time to BF
[PSA < 5 ng/ml (p = 0.311), 5-10 ng/ml (p = 0.309) and
> 10 ng/ml (p = 0.167)] or grade [PSA < 5 ng/ml (p =
0.123), 5-10 ng/ml (p = 0.125) and > 10 ng/ml (p =
0.823)].
In multivariate analysis, only pT stage emerged as
independent prognostic factor of biochemical relapse
(p = 0.01) (Table 3).
Discussion
I nt h i ss t u d yw eh a v es i m u l t a n e o u s l ye x a m i n e dt h e
immunohistochemical expression of p16 and p27 in RP
specimens of hormone naïve PC patients and reported
the absence of a prognostic role for p16 and p27 in pri-
m a r yP C ,a sw eo b s e r v e dn oc o r r e l a t i o n sw i t hm o s t
important, firmly established clinico-pathological para-
meters, including pre-operative PSA, tumor stage and
grade, even at the univariate level. In multivariate analy-
sis including p16, p27, pre-operative PSA level, tumor
stage and Gleason grade, only pT stage retained its
importance in predicting PSA recurrence after RP. In
fact, the risk of PSA relapse was approximately 3.3 fold
greater in patients with advanced pT stage than in men
with early pT stage disease.
Both histological markers have been previously studied
in early PC, often with conflicting results regarding their
putative prognostic relevance. An initial immunohisto-
chemical study of p16 expression in 88 early PC patients
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a higher pre-treatment PSA level and a sooner time to
PSA relapse after RP [6], although p16 was not asso-
ciated with Gleason grade or stage. Unlike our study
population, this cohort followed a higher threshold of
detection (> 5%) for characterization of p16 nuclear
staining in tumor cells. Also, a significant portion of the
cohort (34 patients or 39%) was treated with neo-adju-
vant androgen ablation, which seemed to enhance p16
expression. In multivariate analysis adjusted for tumor
grade, pre-treatment PSA, and stage, overexpression of
p16 did not contribute prognostic information [6].
In contrast, in another study including 104 patients,
high level of p16 protein expression, quantitated by
immunofluorescence flow cytometry, was an independent
predictor of BF, although no significant association was
found between p16 and standard clinico-pathological
variables including serum pre-treatment PSA [19]. This
finding was not sufficiently explicable even by the
authors themselves as they observed no statistically sig-
nificant association between p16 expression and BF in
the same cohort when classic immunohistochemistry was
used as a method of assessment [7].
A larger study of 206 patients with clinically localized
PC evaluated p16 immunohistochemistry in areas of
high-grade intraepithelial neoplasia (HGPIN) and of
cancer in the same specimen. In the cancers, p16 over-
expression, defined as either > 1% or > 5% nuclear stain-
ing, was associated with stage and disease relapse but
did not correlate with age, pre-treatment PSA concen-
tration, or Gleason score. In a multivariate model, over-
expression of p16INK4A in HGPIN was an independent
predictor of disease relapse. Although 38 of the 206
patients in this group received neo-adjuvant hormone
Table 2 Correlations between levels of p16, p27 expression and clinico-pathological characteristics
Variable p16 p27
low high n p value low high n p value
N % n % n % n %
pre-op PSA < 5 10 71.4 4 28.6 14 0.252 12 85.7 2 14.3 14 0.397
5-10 36 75 12 25 48 0.104 39 81.2 9 18.8 48 0.215
>1 0 8 100 0 0 8 0.180 8 100 0 0 8 0.534
Gleason
score
≤ 7 (3+4) 21 72.4 8 27.6 29 0.565 25 86.2 4 13.8 29 1.000
≥ 7 (4+3) 33 80.5 8 19.5 41 34 82.9 7 17.1 41
pT stage ≤ 2 34 80.9 8 19.1 42 0.394 37 88.1 5 11.9 42 0.328
>2 20 71.4 8 28.6 28 22 78.6 6 21.4 28
PSA relapse no 24 72.7 9 27.3 33 0.572 27 81.8 6 18.2 33 1.000
yes 30 81.1 7 18.9 37 31 83.8 6 16.2 37
pre-op PSA, pre-operative PSA; pT stage, pathologic TNM stage
Figure 1 Prostate adenocarcinoma Gleason pattern 3 with high
p27 expression. Strong nuclear immunohistochemical staining for
p27, high expression (> 70%). p27 × 100.
Figure 2 Prostate adenocarcinoma Gleason pattern 3 with low
p27 expression. Nuclear immunohistochemical staining for p27,
low expression (< 70%). p27 × 100.
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Page 4 of 7therapy (NHT) prior to surgery, this did not seem to
influence the prognostic value of p16 expression when
they were excluded from the analyses [20]. In our study
we did not concurrently evaluate the p16 staining status
of HGPIN in our tumor samples, thus our results are
not directly comparable with these of Henshall et al.
Even in this case, they do not mention whether p16
expression in areas of cancer alone independently corre-
lated with relapse-free survival.
Numerous studies have examined the prognostic sig-
nificance of p27 immunohistochemical expression in
RPs, with both negative and positive results. In an early
work, low p27 expression, classified as < 50% of cells
p27 positive, correlated with a number of prognostic
morphologic features (including Gleason score, positive
surgical margins, seminal vesicle involvement, lymph
node metastasis and tumor aneuploidy) but did not cor-
relate with sub-clinical biochemical failure, concurring
with our results [21]. Similarly, Erdamar et al. did not
find any association between the mean labeling index
(LI) of p27Kip1 expression in cancers (LI: 43.5 +/-3.7%,
defined as the percentage of p27-positive cells among
epithelia of the same category) and Gleason score, stage
or disease progression after RP [22]. In another study,
decreased p27Kip1 staining (defined as < 25% of nuclei
stained positive for p27Kip1) correlated with higher
Gleason grade and was an independent predictor of
treatment failure in the node-negative cohort. However,
p27 was not an independent prognostic factor when 24
of 113 patients who underwent pre-operative NHT were
excluded from the analysis [23]. Yang et al. found that
absence of p27kip1 expression was the strongest predic-
tor of biochemical relapse in patients with clinically
organ confined disease [24]. In another cohort, < 10%
reactivity for p27Kip1 proved to be the only indepen-
dent prognostic factor for the PSA recurrence-free sur-
vival of 95 and 86 patients respectively [25,26]. These
studies do not directly contradict our results, given the
differences in cut-off values examined for positivity. A
negative staining reaction as a predictor of recurrence-
free survival did not achieve statistical significance at
other cut-off values (</≥ 40 and </≥ 60% positivity) cal-
culated, which were much closer to the one used in our
study [25].
Cote et al. demonstrated the prognostic value of
decreased p27Kip1 expression (cut-off value of 10%) for
both the recurrence-free and overall survival of 96 PC
patients undergoing RP. However, only stage C patients
were evaluated [27].
At a cut-off level much lower than ours (30% positive
cells), patients with low p27 expression showed a higher
risk of biochemical relapse than the others, which main-
tained its predictive value in a multivariate analysis
Figure 3 Prostate adenocarcinoma Gleason pattern 4 with no
p16 expression. Negative immunoreactivity for p16. p16 × 200.
Figure 4 Prostate adenocarcinoma Gleason pattern 3 with p16
expression. Nuclear immunohistochemical staining for p16 (arrows).
p16 × 200.
Table 3 Multivariate Cox regression analysis
Variable Hazard
ratio
95% Confidence
interval
P
value
Lower
limit
Upper
limit
pre-op PSA < 5 ng/
ml
0.683 0.155 2.681 0.766
pre-op PSA 5-10 ng/
ml
0.838 0.262 3.013 0.639
pre-op PSA > 10 ng/
ml
1.463 0.332 6.449 0.615
Gleason score 1.448 0.586 3.581 0.423
pT stage 3.354 1.342 8.386 0.010
p16 0.643 0.260 1.592 0.340
p27 1.065 0.403 2.813 0.899
pre-op PSA, pre-operative PSA; pT stage, pathologic TNM stage
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patients (47) with available follow up were examined
[28].
Expression of p27 below a median value of 64% in tis-
sue microarrays of 104 patients treated with RP was
associated with high stage, elevated pre-operative PSA
and time to biochemical failure. However, neither p27
alone nor combined PTEN/p27 expression retain their
significance in multivariate analysis [29]. An artifact of
loss of p27 expression during tissue processing in at
least part of the samples of this study remains a possibi-
lity and might explain the different results supported by
our and other groups using individual sample slides.
A negative association of p27 (Kip1) expression with
tumor stage and grade has been reported in a group of 30
PC patients undergoing transurethral resection of the
prostate (TURP) or RP. However, differences in sample
size (only 30 PCs), surgical technique (80% perineal pros-
tatectomy), immunohistochemical evaluation (whole tissue
area), follow up (only 21 months) and cases of biochemical
recurrence (only 7%) do not allow direct comparison
between this study and ours [30]. Likewise, the reported
high frequency of cytoplasmic p27 localization in high
grade tumors compared to low-grade ones [31] cannot be
confirmed by our results, as we performed only nuclear
p27 IHC assessment, consistent with the majority of pre-
vious studies.
In concordance with our results, lack of association
between expression of p27 or its ubiquitin ligase, Skp2,
and time to PSA recurrence was reported in a prospective
study of 162 African-American patients with clinically
localized PC with a cut point for p27 set at < 40% [32].
The most recent study of p27 expression after RP in 100
cases of clinically localized PC, also failed to detect any
association of the former with biochemical recurrence,
although p27 positivity defined as ≥ 40% correlated well
with a lower median pre-operative PSA and a lower Glea-
s o ns c o r e[ 3 3 ] .W h e np 2 7e x p r e s s i o nw a se x a m i n e di na
cohort of 53 patients with pT2 stage disease, no correla-
tion with Gleason score was revealed and p27 had no
prognostic value in predicting biochemical relapse [34].
Another Greek team retrospectively evaluated the prog-
nostic relevance of p27 in 94 patients undergoing RP.
They observed a statistically significant univariate correla-
tion of p27(Kip1) expression, at a level below 30%, with
high pre-operative PSA values and an increased likelihood
of BF after RP. However these data were not confirmed in
multivariate analysis [35].
In the present analysis, we did not observe the strong
correlation between decreased p16 or p27 expression and
PSA recurrence-free survival reported by a part of exist-
ing relevant studies. Possible explanations include the
selection of patients representative of a specific stage in
one study. Also, the inclusion of patients who received
NHT prior to their RP does not consist a homogenous
population let alone that this variable is known to influ-
ence time to PSA relapse after surgery. It is not clear
whether race or different ethnic groups of patients con-
tributed to the difference in the correlation with treat-
ment outcome results.
Most importantly, different methodologies, pathologic
material, and classification schemas for the evaluation of
positivity were used to define p27 expression levels in
other studies. With regard to the cut-off level for positiv-
ity, our intention was to achieve a high sensitivity for
detection of p16 and p27 expression aberrations, based on
the underlying biology. This explains why any positive p16
expression was considered as p16 overexpression whereas
a high cut-off positivity of 70% was used to establish an
early detection of p27 loss in PC tissues.
Several limitations of the present work should be
acknowledged. The small number of patients included in
our study does not permit to draw safe conclusions as 70
patients is a small number of patients in which to identify
an association with outcomes unless the marker examined
is very robust. Lack of compartmental p16, p27 evaluation
and absence of representation of lowest Gleason scores (2,
3, 4) in the study population might have also influenced
the validity of our results. The group of patients studied in
this report may be too homogeneous without sufficient
events to be significant in the time period examined.
Moreover, the prognostic values of these markers might
have been better established if they had been compared to
predicted outcomes of validated nomograms. Finally, our
study was not intended to be all-inclusive of current prog-
nostic markers such as surgical margins, seminal vesicle
invasion, tumor marker ploidy status and proliferation
indices.
Conclusions
Our study was designed in an effort to evaluate the utility
of p16 and p27 assessment in the clinical course of PC
patients. The presence or absence of their significant cor-
relations with established clinical variables as well as of
their interrelations need to be examined in a large pro-
spective cohort, taking into consideration all previous
discordances.
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